These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5890 related articles for article (PubMed ID: 1525402)

  • 1. Phase I trial of Perrimustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
    Kim-Triana B; Misset JL; Madelmont JC; Godenèche D; Musset M; Mathé G
    Anticancer Drugs; 1992 Jun; 3(3):225-31. PubMed ID: 1525402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
    Mathé G; Misset JL; Triana BK; Godenèche D; Madelmont JC; Meyniel G
    Drugs Exp Clin Res; 1992; 18(4):155-8. PubMed ID: 1451646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytostatic action of two nitrosoureas derived from cysteamine.
    Bourut C; Chenu E; Godenèche D; Madelmont JC; Maral R; Mathé G; Meyniel G
    Br J Pharmacol; 1986 Nov; 89(3):539-46. PubMed ID: 3801787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks.
    Creaven PJ; Cowens JW; Huben R; Petrelli N; Karakousis C; Traynor D
    Cancer Chemother Pharmacol; 1989; 23(4):266-7. PubMed ID: 2924383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).
    Vibe-Petersen J; Bork E; Møller H; Hansen HH
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1837-43. PubMed ID: 3436347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I study of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). Phase I Study Group].
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2425-33. PubMed ID: 3729497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
    Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
    Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
    Madelmont JC; Godeneche D; Parry D; Duprat J; Chabard JL; Plagne R; Mathe G; Meyniel G
    J Med Chem; 1985 Sep; 28(9):1346-50. PubMed ID: 4032435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study.
    Earhart RH; Muggia FM; Golomb FM
    Invest New Drugs; 1985; 3(3):297-301. PubMed ID: 4066223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).
    Mathé G; Kidani Y; Triana K; Brienza S; Ribaud P; Goldschmidt E; Ecstein E; Despax R; Musset M; Misset JL
    Biomed Pharmacother; 1986; 40(10):372-6. PubMed ID: 3580505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in small cell cancer of the lung.
    Chapman RA; Natale RB; Young CW; Wittes RE
    Am J Clin Oncol; 1984 Oct; 7(5):413-4. PubMed ID: 6095639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase II study of the water-soluble nitrosourea compound ACNU in advanced colorectal carcinomas].
    Fiebig HH; Wellens W; Peukert M; Henss H; Arnold H; Westerhausen M; Löhr GW
    Onkologie; 1984 Dec; 7(6):370-7. PubMed ID: 6396565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells.
    Godeneche D; Rapp M; Thierry A; Laval F; Madelmont JC; Chollet P; Veyre A
    Cancer Res; 1990 Sep; 50(18):5898-903. PubMed ID: 2393861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours].
    Mathé G; Serrou B; Hayat M; De Vassal F; Misset JL; Schwarzenberg L; Machover D; Ribaud P; Belpomme D; Jasmin C; Musset M; Montero JL; Imbach JL
    Biomedicine; 1977 Nov; 27(8):294-7. PubMed ID: 339971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: a Southwest Oncology Group study.
    Tranum BL; Haut A; Rivkin S; Weber E; Quagliana JM; Shaw M; Tucker WG; Smith FE; Samson M; Gottlieb J
    Cancer; 1975 Apr; 35(4):1148-53. PubMed ID: 1116106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of TCNU, a novel nitrosourea.
    Smyth JF; Macpherson JS; Warrington PS; Kerr ME; Whelan JM; Cornbleet MA; Leonard RC
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1845-9. PubMed ID: 3436348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of PCNU in advanced colorectal carcinoma. An Eastern Cooperative Oncology Group pilot study.
    Earhart RH; Moertel C; Hahn RG; Woodhouse CL; Ramirez G; Engstrom PF
    Am J Clin Oncol; 1984 Aug; 7(4):309-12. PubMed ID: 6741861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of PCNU.
    Kalman LA; Gralla RJ; Casper ES; Kris MG; Gordon C; Woodcock TM
    Cancer Treat Rep; 1983 Nov; 67(11):1027-9. PubMed ID: 6315229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors.
    Feun LG; Stewart DJ; Leavens ME; Burgess MA; Savaraj N; Benjamin RS; Bodey GP
    J Neurooncol; 1983; 1(1):45-8. PubMed ID: 6678305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 295.